MX2022013986A - Métodos para usar interacciones bioadhesivas y estéricas de copolímeros con al menos dos porciones para minimizar los efectos adversos mediados por las influencias externas sobre la biología de células, tejidos, sistemas de órganos y organismos. - Google Patents

Métodos para usar interacciones bioadhesivas y estéricas de copolímeros con al menos dos porciones para minimizar los efectos adversos mediados por las influencias externas sobre la biología de células, tejidos, sistemas de órganos y organismos.

Info

Publication number
MX2022013986A
MX2022013986A MX2022013986A MX2022013986A MX2022013986A MX 2022013986 A MX2022013986 A MX 2022013986A MX 2022013986 A MX2022013986 A MX 2022013986A MX 2022013986 A MX2022013986 A MX 2022013986A MX 2022013986 A MX2022013986 A MX 2022013986A
Authority
MX
Mexico
Prior art keywords
copolymers
bioadhesive
moieties
cell
tissue
Prior art date
Application number
MX2022013986A
Other languages
English (en)
Inventor
David M Kleinman
Original Assignee
Calm Water Therapeutics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Calm Water Therapeutics Llc filed Critical Calm Water Therapeutics Llc
Publication of MX2022013986A publication Critical patent/MX2022013986A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N33/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic nitrogen compounds
    • A01N33/02—Amines; Quaternary ammonium compounds
    • A01N33/08—Amines; Quaternary ammonium compounds containing oxygen or sulfur
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01P—BIOCIDAL, PEST REPELLANT, PEST ATTRACTANT OR PLANT GROWTH REGULATORY ACTIVITY OF CHEMICAL COMPOUNDS OR PREPARATIONS
    • A01P1/00—Disinfectants; Antimicrobial compounds or mixtures thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pest Control & Pesticides (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Agronomy & Crop Science (AREA)
  • Dentistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Métodos para usar interacciones bioadhesivas y estéricas específicas de copolímeros con al menos dos porciones, para minimizar los efectos adversos mediados por influencias externas en la biología de células, tejidos, órganos y organismos. Los copolímeros tienen propiedades bioadhesivas impulsadas por interacciones electrostáticas e hidrofóbicas y de pasivación a través de porciones hidrofílicas. Estos copolímeros son útiles para reducir las tasas de infectividad viral en las células blanco y para reducir la morbilidad del hospedero. Estos copolímeros son útiles para reducir la toxicidad relacionada con ADC, incluyendo la toxicidad epitelial de la córnea. Las formulaciones de estos copolímeros son seguras y bien toleradas. Las células y superficies epiteliales, incluyendo las células epiteliales de la córnea precursoras o de células madre, se tratan con estos copolímeros para conferirles utilidad y beneficio.
MX2022013986A 2020-05-07 2021-05-07 Métodos para usar interacciones bioadhesivas y estéricas de copolímeros con al menos dos porciones para minimizar los efectos adversos mediados por las influencias externas sobre la biología de células, tejidos, sistemas de órganos y organismos. MX2022013986A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063021277P 2020-05-07 2020-05-07
PCT/US2021/031266 WO2021226441A1 (en) 2020-05-07 2021-05-07 Methods for using bioadhesive and steric interactions of copolymers with at least two moieties to minimize adverse effects mediated by external influences on cell, tissue, organ system, and organism biology

Publications (1)

Publication Number Publication Date
MX2022013986A true MX2022013986A (es) 2023-02-09

Family

ID=78468432

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022013986A MX2022013986A (es) 2020-05-07 2021-05-07 Métodos para usar interacciones bioadhesivas y estéricas de copolímeros con al menos dos porciones para minimizar los efectos adversos mediados por las influencias externas sobre la biología de células, tejidos, sistemas de órganos y organismos.

Country Status (9)

Country Link
US (1) US20230201251A1 (es)
EP (1) EP4145997A4 (es)
JP (1) JP2023534360A (es)
CN (1) CN116209453A (es)
AU (1) AU2021267928A1 (es)
BR (1) BR112022022480A2 (es)
CA (1) CA3182679A1 (es)
MX (1) MX2022013986A (es)
WO (1) WO2021226441A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022051713A1 (en) * 2020-09-04 2022-03-10 The University Of Chicago Materials and methods of treating viral infection with amphiphilic block copolymers

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2398499B1 (en) * 2009-02-18 2017-09-06 Eyeon Particle Sciences LLC Bi-functional co-polymer use for ophthalmic and other topical and local applications

Also Published As

Publication number Publication date
CN116209453A (zh) 2023-06-02
US20230201251A1 (en) 2023-06-29
BR112022022480A2 (pt) 2023-01-10
JP2023534360A (ja) 2023-08-09
EP4145997A1 (en) 2023-03-15
EP4145997A4 (en) 2024-05-29
CA3182679A1 (en) 2021-11-11
WO2021226441A1 (en) 2021-11-11
AU2021267928A1 (en) 2023-01-19

Similar Documents

Publication Publication Date Title
Cai et al. Green synthesis of gold nanoparticles for immune response regulation: Mechanisms, applications, and perspectives
Yahaya et al. Evaluation of Trametes lactinea extracts on the inhibition of hyaluronidase, lipoxygenase and xanthine oxidase activities in vitro
BR112021026241A2 (pt) Compostos de benzil-triazol substituído para inibição de cbl-b e outros usos dos mesmos
MX2022013986A (es) Métodos para usar interacciones bioadhesivas y estéricas de copolímeros con al menos dos porciones para minimizar los efectos adversos mediados por las influencias externas sobre la biología de células, tejidos, sistemas de órganos y organismos.
WO2005044179A8 (en) Formulations containing astragalus extracts and uses thereof
MX2012000547A (es) Copolimero hidrofobicamente asociativo, soluble en agua.
NZ611981A (en) Treatment of immune-related diseases and disorders using amnion derived adherent cells
WO2005000245A3 (en) Compositions and methods for increasing telomerase activity
Drake et al. Transformation of Althaea officinalis L. by Agrobacterium rhizogenes for the production of transgenic roots expressing the anti-HIV microbicide cyanovirin-N
Sun et al. Respiratory mucosal vaccination of peptide-poloxamine-DNA nanoparticles provides complete protection against lethal SARS-CoV-2 challenge
CN110123829A (zh) 长链非编码rna在制备肿瘤血管形成抑制剂中的应用
CN106566808A (zh) 过氧化氢诱导的猪肺泡巨噬细胞系氧化应激模型的建立方法
WO2024151745A3 (en) Targeted anti-prdm compositions and uses thereof
MX2022015205A (es) Integracion dirigida de acidos nucleicos.
Zhang et al. Anti-inflammatory bone protective effects of nano-protein extracts from mushroom species: Ganoderma lucidum and Pleurotus ostreatus
ATE454164T1 (de) Francisella-stamm für lebenden impfstoff
Buranrat et al. Comparative study on the effect of aqueous and ethanolic mycelial extracts from Polycephalomyces nipponicus (Ascomycetes) against human breast cancer MCF-7 cells
Gordon et al. The role of herpesvirus type 1 thymidine kinase in experimental ocular infections
CN107475126B (zh) 一种蚕蛹虫草培养基
Samer et al. Evidence of noncompetent HIV after ex vivo purging among ART-suppressed individuals
Kovalenko et al. Virus Resistance induced by glucuronoxylomannan isolated from submerged cultivated yeast-like cell biomass of medicinal yellow brain mushroom Tremella mesenterica Ritz.: Fr.(Heterobasidiomycetes) in hypersensitive host plants
WO2023081891A3 (en) Methods for using bioadhesive and steric interactions of copolymers to minimize adverse effects
Abdelwahab et al. Potential antiviral activity of metformin against human Adenovirus-7
Kwon et al. Functions of Herpesvirus-Encoded Homologs of the Cellular Ribonucleotide Reductase Large Subunit
Dawut et al. Biocontrol Potentiality of Active Ingredients from Endophytic Bacillus subtilis Isolated from Alhagi pseudalhagi Desv on Maize Spot Diseases